News25/Ratings5
Price$23.43-2.68 (-10.26%)
2026-02-062026-04-24
News · 26 weeks48-100%
2025-11-022026-04-26
Mix4890d
- Insider30(63%)
- Other6(13%)
- SEC Filings5(10%)
- Analyst5(10%)
- Offering2(4%)
Latest news
25 items- SECSEC Form 10-K filed by SpyGlass Pharma Inc.10-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate UpdateSuccessfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that demonstrated sustained intraocular pressure (IOP) control, elimination of IOP-lowering eye drops for 97% of trial participants, and improved visual performance, with a favorable safety profile.Phase 3 trials of BIM-IOL System are ongoing, with enrollment underway and full enrollment expected in 2027.Cash, cash equivalents and short-term investments expected to fund planned operations through 2028. ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- S
- ANALYSTH.C. Wainwright initiated coverage on SpyGlass Pharma with a new price targetH.C. Wainwright initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $37.00
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, performance in line with the state-of-the-art IOLs in the control groupOverall safety results were comparable to routine cataract surgery ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for th
- PRSpyGlass Pharma to Participate in the Jefferies Biotech on the Beach SummitALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing dur
- ANALYSTStifel initiated coverage on SpyGlass Pharma with a new price targetStifel initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00
- ANALYSTCitigroup initiated coverage on SpyGlass Pharma with a new price targetCitigroup initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00
- ANALYSTJefferies initiated coverage on SpyGlass Pharma with a new price targetJefferies initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $62.00
- ANALYSTLeerink Partners initiated coverage on SpyGlass Pharma with a new price targetLeerink Partners initiated coverage of SpyGlass Pharma with a rating of Outperform and set a new price target of $42.00
- SECSEC Form SCHEDULE 13G filed by SpyGlass Pharma Inc.SCHEDULE 13G - SpyGlass Pharma, Inc. (0001778922) (Subject)
- SECSEC Form SCHEDULE 13D filed by SpyGlass Pharma Inc.SCHEDULE 13D - SpyGlass Pharma, Inc. (0001778922) (Subject)
- SECSEC Form SCHEDULE 13D filed by SpyGlass Pharma Inc.SCHEDULE 13D - SpyGlass Pharma, Inc. (0001778922) (Subject)
- SECSEC Form SCHEDULE 13D filed by SpyGlass Pharma Inc.SCHEDULE 13D - SpyGlass Pharma, Inc. (0001778922) (Subject)
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Leadership Update8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- INSIDERDirector Ra Capital Management, L.P. converted options into 4,331,117 shares and bought $59,040,000 worth of shares (3,690,000 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Nielsen Kirk G.4/A - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERLarge owner Florence Anthony A. Jr. converted options into 6,454,801 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERDirector Behbahani Ali converted options into 6,454,801 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERLarge owner Yang Rick converted options into 5,097,538 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERLarge owner Baskett Forest converted options into 6,454,801 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERLarge owner New Enterprise Associates 17, L.P. converted options into 5,097,538 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERLarge owner Makhzoumi Mohamad converted options into 6,454,801 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
- INSIDERLarge owner Sandell Scott D converted options into 6,454,801 shares and bought $15,000,000 worth of shares (937,500 units at $16.00) (SEC Form 4)4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)